高级检索
当前位置: 首页 > 详情页

A novel protoapigenone analog RY10-4 induces breast cancer MCF-7 cell death through autophagy via the Akt/mTOR pathway

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

单位: [1]Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Pharm, Key Lab Nat Med Chem & Resource Evaluat Hubei Pro, Wuhan 430030, Hubei Province, Peoples R China [2]Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Pharm, Tongji Hosp, Wuhan 430030, Hubei Province, Peoples R China
出处:
ISSN:

关键词: RY10-4 Protoapigenone Autophagy Breast cancer mTOR

摘要:
Protoapigenone is a unique flavonoid and enriched in many ferns, showing potent antitumor activity against a broad spectrum of human cancer cell lines. RY10-4, a modified version of protoapigenone, manifested better anti-proliferation activity in human breast cancer cell line MCF-7. The cytotoxicity of RY10-4 against MCF-7 cells is exhibited in both time- and concentration-dependent manners. Here we investigated a novel effect of RY10-4 mediated autophagy in autophagy defect MCF-7 cells. Employing immunofluorescence assay for microtubule-associated protein light-chain 3 (LC3), monodansylcadaverine staining, Western blotting analyses for LC3 and p62 as well as ultrastructural analysis by transmission electron microscopy, we showed that RY10-4 induced autophagy in MCF-7 cells but protoapigenone did not. Meanwhile, inhibition of autophagy by pharmacological and genetic approaches significantly increased the viability of RY10-4 treated cells, suggesting that the autophagy induced by RY10-4 played as a promotion mechanism for cell death. Further studies revealed that RY10-4 suppressed the activation of mTOR and p70S6K via the Akt/mTOR pathway. Our results provided new insights for the mechanism of RY10-4 induced cell death and the cause of RY10-4 showing better antitumor activity than protoapigenone, and supported further evidences for RY10-4 as a lead to design a promising antitumor agent. (C) 2013 Elsevier Inc. All rights reserved.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2012]版:
大类 | 2 区 医学
小类 | 2 区 药学 2 区 毒理学
最新[2025]版:
大类 | 3 区 医学
小类 | 2 区 毒理学 3 区 药学
JCR分区:
出版当年[2011]版:
Q1 PHARMACOLOGY & PHARMACY Q1 TOXICOLOGY
最新[2023]版:
Q2 PHARMACOLOGY & PHARMACY Q2 TOXICOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2011版] 出版当年五年平均 出版前一年[2010版] 出版后一年[2012版]

第一作者:
第一作者单位: [1]Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Pharm, Key Lab Nat Med Chem & Resource Evaluat Hubei Pro, Wuhan 430030, Hubei Province, Peoples R China
通讯作者:
通讯机构: [1]Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Pharm, Key Lab Nat Med Chem & Resource Evaluat Hubei Pro, Wuhan 430030, Hubei Province, Peoples R China [*1]Huazhong Univ Sci & Technol, Tongji Med Coll, 13 Hangkong Rd, Wuhan 430030, Hubei Province, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:428 今日访问量:2 总访问量:412 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)